A promising obesity and diabetes drug stumbles in Alzheimer's trials, rattling markets. Did investors overreact, or is this a ...

The company said the weight loss and diabetes treatment drug failed to show any significant reduction in the progression of ...

Novo Nordisk’s stock tumbles after its oral GLP-1 drug didn’t show a statistically significant benefit over a placebo against ...

A long-shot Ozempic trial collapse sends Novo Nordisk to its lowest levels since 2021, reigniting market fears.

Novo Nordisk shares plunge after semaglutide Alzheimer’s trial fails to meet its main goal, deepening pressure amid ...

Novo's upcoming Alzheimer's trial results will test whether Rybelsus can slow cognitive decline and reshape treatment expectations for GLP-1 drugs.

COPENHAGEN, Feb 3 (Reuters) - Diabetes drugmaker Novo Nordisk (NOVOb.CO), opens new tab forecast a rise in underlying sales and profit for 2021 on Wednesday and said it expected more Americans to get ...

A 2.3% quarterly jump, according to Statistics Denmark, was powered almost entirely by the pharmaceutical engine dominated by Novo Nordisk (NYSE:NVO), turning an otherwise modest 0.7% non-pharma ...

Reuters warns that Novo Nordisk's growth rate is slowing. Singapore bank DBS says the stock is a sell. But at 18 times earnings and with a growth rate of 16% or better, Novo Nordisk actually looks ...

The weather in Lexington, Massachusetts, may have been rainy and dreary Wednesday, but the mood inside Novo Nordisk’s new U.S. R&D homebase was anything but. Scientists, stakeholders, executives and ...

Late last month, Novo Holdings’ CEO Kasim Kutay hinted that the fund manager was eyeing buyouts as an outlet for its trove of Wegovy cash. Now, a major deal has materialized. Novo Holdings, which ...

As demand continues to surge for the Ozempic-Wegovy duo of diabetes and obesity meds, Novo Nordisk is investing heavily to boost production capacity. Novo will shell out more than 42 billion Danish ...